Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 third quarter ended December 31, 2025, and provided a corporate update.
“We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization, and operational enhancements to our ongoing PALISADE-4 Phase 3 trial. We expect topline results from the randomized portion of PALISADE-4 in the first half of 2026,” said Shawn Singh, President and Chief Executive Officer of Vistagen. “With outside collaborators and their proprietary artificial intelligence and machine learning methodologies, we are conducting an extensive analysis across all available PALISADE Program datasets to potentially inform modifications to the statistical analysis plan for PALISADE-4 and our regulatory strategy.”
“We have implemented targeted, company-wide cash preservation initiatives and remain committed to disciplined capital allocation and preserving strategic flexibility as we approach key clinical milestones in 2026. We believe we are well-positioned to complete PALISADE-4 and advance preparations and planning for the pherine pipeline.”
Program Updates
Fasedienol for the Acute Treatment of Social Anxiety Disorder
Refisolone (formerly PH80) for the treatment of vasomotor symptoms (hot flashes) due to menopause
Corporate Updates
Financial Results for Fiscal Year 2026 Third Quarter Ended December 31, 2025
Research and development (R&D) expense
General and administrative (G&A) expense
Net loss
Other financial highlights
Conference Call and Webcast
Vistagen will host a conference call and live audio webcast today, February 12, 2026, at 5:00 p.m. Eastern Time to provide a corporate update of the Company’s progress. The conference call is being webcast live, and a link can be found under “Events” in the Investors section of Vistagen's website. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes before the call. The webcast will be archived on Vistagen’s website shortly after the call and will be available for at least 90 days.
For participants interested in participating in the call via dial-in, please follow the link below to pre-register. After registering, you will be provided with access details via email.
https://edge.media-server.com/mmc/p/mggzveh9/
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen’s pherine pipeline currently consists of five investigational product candidates focused on improving the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause. Connect at www.Vistagen.com.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including, without limitation, Vistagen’s anticipated timing for the announcement of top-line results from the randomized portion of PALISADE-4, potential of analyses across the PALISADE Program datasets to modify the statistical analysis plan for PALISADE-4 and Vistagen’s regulatory strategy, Vistagen’s belief that company-wide cash preservation initiatives will enable Vistagen to complete PALISADE-4 and advance preparations and planning for the pherine pipeline, and Vistagen’s plans to submit an IND to the FDA to facilitate further Phase 2 clinical development of refisolone in the U.S. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization, and actual results or developments may differ materially from those projected or implied in these forward-looking statements. There can be no guarantee that any of Vistagen’s product candidates, including fasedienol, will successfully complete ongoing or future clinical trials within estimated timelines or at all, receive regulatory approval or be commercially successful. Other factors that may cause such a difference include, without limitation, risks and uncertainties relating to conducting and/or completing ongoing clinical trials, including those that are a part of the PALISADE Phase 3 program for fasedienol in social anxiety disorder, as currently expected or at all; Vistagen’s ability to ability to successfully employ cash preservation measures and/or secure adequate financing for its operations, including financing or collaborative support for continued clinical development of its product candidates; Vistagen's dependence on third-party collaborators for the development, regulatory approval, and/or commercialization of its product candidates and other aspects of its business, which are outside of Vistagen's full control; risks and uncertainties resulting from disruptions and personnel turnover, staff reductions or otherwise, either within Vistagen or at the FDA, other government agencies and comparable foreign regulatory authorities; risks associated with current and potential future healthcare reforms; the scope and enforceability of Vistagen’s patents, including patents related to Vistagen’s pherine product candidates; fluctuating costs of materials and other resources and services required to conduct Vistagen’s ongoing and/or planned clinical and non-clinical trials; market conditions; the impact of general economic, industry or political conditions in the United States or internationally; and other technical and unexpected hurdles in the development, manufacture and commercialization of Vistagen’s product candidates. These risks and others are more fully discussed in the section entitled “Risk Factors” in Vistagen’s Quarterly Report on Form 10-Q for the period ended December 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the U.S. Securities and Exchange Commission (SEC). Vistagen’s SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen’s views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements.
VISTAGEN THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and par value amounts)
December 31,
2025
March 31,
2025
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
47,371
$
67,131
Marketable securities
14,399
13,351
Prepaid expenses and other current assets
1,475
1,594
Total current assets
63,245
82,076
Property and equipment, net
480
476
Right-of-use asset - operating lease
939
1,335
Other assets
392
454
Total assets
$
65,056
$
84,341
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
$
1,280
$
653
Accrued expenses
9,254
8,810
Note payable
379
—
Deferred revenue - current portion
1,999
2,588
Operating lease obligation - current portion
617
561
Total current liabilities
13,529
12,612
Deferred revenue - non-current portion
176
391
Operating lease obligation - non-current portion
431
948
Total liabilities
14,136
13,951
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and March 31, 2025; no shares outstanding at December 31, 2025 and March 31, 2025
—
—
Common stock, $0.001 par value; 325,000,000 shares authorized at December 31, 2025 and March 31, 2025; 39,624,839 and 29,001,481 shares issued at December 31, 2025 and March 31, 2025, respectively
40
29
Additional paid-in capital
515,878
481,956
Treasury stock, at cost, 4,522 shares of common stock held at December 31, 2025 and March 31, 2025
(3,968
)
(3,968
)
Accumulated other comprehensive income
13
5
Accumulated deficit
(461,043
)
(407,632
)
Total stockholders’ equity
50,920
70,390
Total liabilities and stockholders’ equity
$
65,056
$
84,341
VISTAGEN THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except share and per share data)
Three Months Ended
December 31,
Nine Months Ended
December 31,
2025
2024
2025
2024
Revenues:
Sublicense and other revenue
$
303
$
234
$
804
$
501
Total revenues
303
234
804
$
501
Operating expenses:
Research and development
14,223
11,305
41,914
$
29,168
General and administrative
5,626
4,049
14,299
$
12,811
Total operating expenses
19,849
15,354
56,213
$
41,979
Loss from operations
(19,546
)
(15,120
)
(55,409
)
$
(41,478
)
Other income, net:
Interest income, net
647
1,031
1,989
$
3,702
Other income
—
—
9
—
Loss before income taxes
(18,899
)
(14,089
)
(53,411
)
(37,776
)
Income taxes
—
—
—
$
(7
)
Net loss
$
(18,899
)
$
(14,089
)
$
(53,411
)
$
(37,783
)
Unrealized gain (loss) on marketable securities
(1
)
(11,000
)
8
11
Comprehensive loss
$
(18,900
)
$
(14,100
)
$
(53,403
)
$
(37,772
)
Basic and diluted net loss per common share
$
(0.45
)
$
(0.46
)
$
(1.46
)
$
(1.23
)
Weighted average common shares outstanding, basic and diluted
42,234,405
30,711,872
36,655,195
30,649,384